An estradiol patch delivers estrogen through the skin. It is a prescription medicine with labeled warnings, and some of those warnings are being revised during 2026. This guide covers the common side effects listed on the label, how to handle skin and adhesion problems, what the boxed warning says now, and what may differ between a patch and a pill. It is educational, not medical advice.

Common side effects on the label

In pooled trials of a once-weekly estradiol patch, the most common side effects, each reported by at least 10% of users, were breast pain, upper respiratory infections, headaches, abdominal pain, general pain, and swelling (edema) [1].

The label's warnings section also covers less common effects, including fluid retention, gallbladder disease, and worsening of conditions such as migraine, asthma, and epilepsy in some people [1]. Report any unexpected vaginal bleeding to your provider, since the label calls for evaluation of unexplained bleeding [1].

Skin and adhesion: What the label says

Most day-to-day patch problems are about the skin. The once-weekly label gives these instructions [1]:

  • Where to apply: a clean, dry area of the lower abdomen or upper buttock. Never on or near the breasts.
  • Rotate sites: leave at least one week before reusing the same spot.
  • Avoid: oily, damaged, or irritated skin, and the waistline, where clothing can rub the patch off.
  • If it falls off: reapply it to a different spot. If it will not stick, apply a new patch for the rest of the seven-day interval. Wear only one patch at a time.
  • Water and heat: swimming, bathing, and saunas were not studied and may loosen the patch.
  • Removing it: peel slowly to avoid irritating the skin. For leftover adhesive, let the area dry for 15 minutes, then gently rub with an oil-based cream or lotion. Fold the used patch in half before throwing it away.

If redness, itching, or a rash at the site lasts or spreads, tell your provider.

The boxed warning, and how it is changing

For years, estrogen products carried a boxed warning covering four topics: endometrial cancer, cardiovascular disorders, probable dementia, and breast cancer. The once-weekly patch label we reviewed, dated June 2025, still carries all four [1].

In November 2025, the FDA began asking manufacturers to remove the cardiovascular, breast cancer, and dementia statements from the boxed warning, while keeping the boxed warning for endometrial cancer on systemic estrogen-alone products [2]. In February 2026, the FDA approved the first six updated labels [3, 4]. Other manufacturers are updating on their own timelines, so the label that comes with your patch may show either version.

Moving a statement out of the box does not erase the underlying risk. These points still apply:

  • Endometrial cancer. Using estrogen alone, without a progestogen, raises the risk of endometrial cancer in a woman who still has a uterus. The label describes a risk about 2 to 12 times that of non-users, rising with dose and length of use [1]. Adding a progestogen has been shown to lower the risk of endometrial hyperplasia, a possible precursor [1]. If you have a uterus, ask your provider whether you need one.
  • Blood clots and stroke. The label reports increased risks of stroke and deep vein thrombosis with estrogen-alone therapy and says to stop immediately if either is suspected [1].
  • Breast cancer. The label notes that observational studies have reported higher breast cancer risk after several years of hormone therapy, larger with estrogen plus progestin than with estrogen alone [1]. It recommends yearly breast exams and mammograms based on age and risk [1].

What may be different about the patch

Many of the large-trial numbers on estrogen labels come from the Women's Health Initiative, which studied oral estrogen. The patch label itself says the relevance of those findings to other routes of administration is not known [1].

The Menopause Society's 2022 position statement notes that transdermal routes and lower doses may decrease the risk of venous thromboembolism and stroke [5]. "May" is the operative word: it is a reason to discuss route with your provider, not a guarantee.

For a side-by-side look at delivery options, see Estradiol delivery methods compared.

Does the patch cause weight gain?

Swelling (edema) is among the label's most common side effects, and the label warns that estrogen can cause some fluid retention [1]. If your weight or swelling changes in a way that concerns you, raise it with your provider rather than adjusting or removing the patch yourself.

Who should not use estradiol

The label lists these contraindications [1]:

  • Unexplained abnormal genital bleeding
  • Current or past breast cancer, or other estrogen-dependent cancer
  • Active or past blood clots in the legs or lungs
  • Active or past arterial clotting disease, such as stroke or heart attack
  • Liver disease
  • Known protein C, protein S, or antithrombin deficiency, or another clotting disorder
  • A past allergic reaction to the patch

These are not comprehensive lists of risks or contraindications; patients should review the prescribing information and discuss their medical history with their clinician.

Share your full history, including migraine, gallbladder problems, and any thyroid medication. Ongoing monitoring runs through your own clinician. For more on fit, see Who should consider HRT.

Like any prescription medication, estradiol carries risks and possible side effects your provider will review with you. See also HRT side effects and modern evidence.

Common questions

Is the patch better than the pill?
Neither is better for everyone. The difference most often discussed is clot risk, which may be lower with transdermal routes [5]. Your history and preferences decide which fits.

How long do side effects last?
We did not find label data on how long individual side effects last. If one persists or gets worse, tell your provider.

What doses do patches come in?
The once-weekly label lists strengths from 0.025 mg to 0.1 mg per day, starting at 0.025 mg per day and adjusting based on response [1]. Other patch products have their own schedules. See the estradiol patches page.

Can I cut a patch?
The label gives no instructions for cutting. Do not change the patch yourself; ask your pharmacist or provider.

Next steps

If any of this sounds like what you are dealing with, the next step is a conversation with a licensed provider who can review your history and decide whether treatment makes sense for you. Nothing is prescribed or shipped without that review. Any medication preference you indicate is only a starting point for discussion. A licensed clinician independently determines whether prescription treatment is medically appropriate and, if so, which medication, dose, and treatment plan are appropriate based on your clinical evaluation.

Explore Luvo's Hormone Replacement Program.

Sources

  1. Estradiol transdermal system, continuous delivery (once-weekly), prescribing information. Revised 06/2025. FDALabel. https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/e7e6da3b-8485-1382-61c9-e9b369018b98/spl-doc
  2. U.S. Food and Drug Administration. "HHS Advances Women's Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy." November 10, 2025. Accessed 2026-10-26. https://www.fda.gov/news-events/press-announcements/hhs-advances-womens-health-removes-misleading-fda-warnings-hormone-replacement-therapy-1
  3. U.S. Food and Drug Administration. "FDA Approves Labeling Changes to Menopausal Hormone Therapy Products." Content current as of 2026-02-12. Accessed 2026-10-26. https://www.fda.gov/news-events/press-announcements/fda-approves-labeling-changes-menopausal-hormone-therapy-products
  4. U.S. Food and Drug Administration. "Menopausal Hormone Therapies with Updated Prescribing Information." Content current as of 2026-02-12. Accessed 2026-10-26. https://www.fda.gov/drugs/drug-safety-and-availability/menopausal-hormone-therapies-updated-prescribing-information
  5. The North American Menopause Society. "The 2022 hormone therapy position statement of The North American Menopause Society." Menopause. 2022;29(7):767-794. doi:10.1097/GME.0000000000002028. https://doi.org/10.1097/GME.0000000000002028

This article is for general educational purposes and is not medical advice. It is not a substitute for a conversation with a licensed healthcare provider about your own health. Prescription treatments require provider review and approval. Individual results vary.

If your symptoms are severe, worsening, or new, contact a healthcare provider. If this is an emergency, call 911 or go to the nearest emergency room.